Thank you very much for the question. It's an important one. It's actually a worldwide question as well, because there are over 400 different studies going on in the world right now, looking at a whole variety of things.
Let's take your example of a protease inhibitor. If it is shown to have efficacy, the way that these studies have been designed and the way the funding has moved forward mean that this would move forward rapidly to scale up without having to worry about the IP protection component in there.
Obviously at some point down the road, yes, there's going to have to be a conversation around that, but not in the midst of a pandemic. We are looking very carefully and critically with our governmental partners right now at what this next phase will look like, because what we have funded through the first phase will identify these extremely promising candidates. Now we need to move to the next phase. That's where the work is happening as we speak.